Table 2.

Univariate and multivariate Cox proportional hazard analysis of OS and TTR

OSTTR
UnivariateMultivariateUnivariateMultivariate
CharacteristicTotal nHR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)P
CIMP/MLH1 methylation status0.011<0.0010.0620.023
 CIMP−/MLH1-U701.00 (Referent)1.00 (Referent)1.00 (Referent)1.00 (Referent)
 CIMP+/MLH1-U152.76 (1.46–5.19)0.0024.73 (2.34–9.54)<0.0012.26 (1.04–4.88)0.0393.33 (1.39–8.00)0.007
 CIMP+/MLH1-M120.80 (0.31–2.07)0.6490.43 (0.15–1.24)0.1170.21 (0.03–1.57)0.2120.26 (0.03–2.10)0.204
 CIMP−/MLH1-M20 (0, −)0.9710 (0, −)0.9730 (0, −)0.9770 (0, −)0.978
Age
 <70641.00 (Referent)1.00 (Referent)1.00 (Referent)1.00 (Referent)
 ≥70351.73 (0.99–3.00)0.0532.65 (1.42–4.92)0.0020.27 (0.09–0.75)0.0130.47 (0.15–1.41)0.177
Sex
 Male551.00 (Referent)1.00 (Referent)1.00 (Referent)1.00 (Referent)
 Female440.96 (0.55–1.67)0.8871.45 (0.80–2.65)0.2210.50 (0.24–1.03)0.0610.90 (0.42–1.94)0.790
Stage
 Stage I and II291.00 (Referent)1.00 (Referent)1.00 (Referent)1.00 (Referent)
 Stage III and IV702.72 (1.35–5.45)0.0055.27 (2.25–12.38)<0.0014.88 (1.71–13.97)0.0034.28 (1.26–14.50)0.020
Differentiation
 Well/moderately551.00 (Referent)1.00 (Referent)1.00 (Referent)1.00 (Referent)
 Poorly441.65 (0.95–2.87)0.0781.42 (0.78–2.56)0.2523.01 (1.48–6.12)0.0022.27 (1.06–4.84)0.034
Chemotherapy/radiotherapy
 No381.00 (Referent)1.00 (Referent)1.00 (Referent)1.00 (Referent)
 Yes611.42 (0.79–2.57)0.2461.10 (0.55–2.20)0.7783.67 (1.49–9.03)0.0051.87 (0.71–4.92)0.203
KRAS mutations
 Absent671.00 (Referent)1.00 (Referent)1.00 (Referent)1.00 (Referent)
 Present321.09 (0.61–1.95)0.7720.64 (0.34–1.20)0.1601.02 (0.50–2.09)0.9600.51 (0.22–1.17)0.111

Abbreviations: MLH1-M, MLH1-methylated; MLH1-U, MLH1-unmethylated.